Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer · 2023-04 · 11 (4) · e006406
DOI: 10.1136/jitc-2022-006406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.04.2023. Verfasst von Olaf Penack und 25 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany olaf.penack@charite.de. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Anemia. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T-cells with axicel (62%) or tisacel (38%) before August 2021 and had cytopenia status documented for the first 100 days. Most patients had received two or three previous lines of therapy, however, 22.3% had received four or more. Disease status was progressive in 80.4%, stable in 5.0% and partial/complete remission in 14.6%. 25.9% of the patients had received a transplantation before. Median age was 61.4 years (min–max; IQR=18.7–81; (52.9–69.5)). The cumulative incidence of ≥grade 3 cytopenia was 9.0% at 30 days (95% CI (6.5 to 12.1)) and 12.1% at 100 days after CAR T-cell infusion (95% CI (9.1 to 15.5)). The median time from CAR-T infusion to cytopenia onset was 16.5 days (min–max; IQR=1–90; (4–29.8)). Grade 3 and grade 4 CTCAE cytopenia occurred in 15.2% and 84.8%, respectively. In 47.6% there was no resolution. Severe cytopenia had no significant impact on overall survival (OS) (HR 1.13 (95% CI 0.74 to 1.73), p=0.57). However, patients with severe cytopenia had a poorer progression-free survival (PFS) (HR 1.54 (95% CI 1.07 to 2.22), p=0.02) and a higher relapse incidence (HR 1.52 (95% CI 1.04 to 2.23), p=0.03). In those patients who developed severe cytopenia during the first 100 days (n=47), OS, PFS, relapse incidence and non-relapse mortality at 12 months after diagnosis of severe cytopenia were 53.6% (95% CI (40.3 to 71.2)), 20% (95% CI (10.4 to 38.6)), 73.5% (95% CI (55.2 to 85.2)) and 6.5% (95% CI (1.7 to 16.2)), respectively. In multivariate analysis of severe cytopenia risk factors, only year of CAR-T infusion (HR=0.61, 95% CI (0.39 to 0.95), p=0.028) and total number of treatment lines before CAR-T infusion (one or two lines vs three or more, HR=0.41, 95% CI (0.21 to 0.83), p=0.013) had a significant positive association with the incidence of cytopenia. Other factors, such as previous transplantation, disease status at time of CAR-T, patient age and patient sex, had no significant association. Our data provide insight on frequency and clinical relevance of severe cytopenia after CAR T-cell therapy in the European real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany olaf.penack@charite.de.
- EBMT Transplant Complications Working Party, Paris, France.
- EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR-S 938, Sorbonne University, Paris, France.
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Departement of Haematological Medicine, Kings College Hospital, London, UK.
- Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, Languedoc-Roussillon, France.
ORCID-Profile: Olaf Penack, Christian Chabannon, Rafael de la Camara
Zitieren
APA
Penack, O., Peczynski, C., Koenecke, C., Polge, E., Kuhnl, A., Fegueux, N., Daskalakis, M., Kröger, N., Dreger, P., Besley, C., Schanz, U., Bloor, A., Ganser, A., Forcade, E., Corral, L. L., Passweg, J. R., Novak, U., Moiseev, I., Schoemans, H., …, & Peric, Z. (2023). Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer, 11(4), e006406. https://doi.org/10.1136/jitc-2022-006406
Vancouver
Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer. 2023;11(4):e006406. doi:10.1136/jitc-2022-006406
BibTeX
@article{Penack2023,
author = {Penack, Olaf and Peczynski, Christophe and Koenecke, Christian and Polge, Emmanuelle and Kuhnl, Andrea and Fegueux, Nathalie and Daskalakis, Michael and Kröger, Nicolaus and Dreger, Peter and Besley, Caroline and Schanz, Urs and Bloor, Adrian and Ganser, Arnold and Forcade, Edouard and Corral, Lucia López and Passweg, Jakob R and Novak, Urban and Moiseev, Ivan and Schoemans, Hélène and Basak, Grzegorz W and Chabannon, Christian and Sureda, Anna and Averbuch, Dina and Glass, Bertram and de la Camara, Rafael and Peric, Zinaida},
title = {Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {4},
pages = {e006406},
doi = {10.1136/jitc-2022-006406}
}
EUVIMED